Trials / Completed
CompletedNCT00657891
The Effect of Xolair (Omalizumab) on Allergy Blood Cells
The Effect of Xolair (Omalizumab) on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Creighton University · Academic / Other
- Sex
- All
- Age
- 16 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
We are studying Xolair (omalizumab) to see it's effect on allergic blood cells. The blood tests will be done in a test tube to see if they react differently before and after treatment. The blood cells will be mixed with to whatever the person is allergic.
Detailed description
Must be allergic-asthma with IgE between 30 and 700 IU/ml.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omalizumab | 0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously |
| DRUG | Placebo | Placebo Injection |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2008-04-14
- Last updated
- 2013-10-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00657891. Inclusion in this directory is not an endorsement.